@springermedicine.comFrom #EURETINA2026 - Two investigational gene therapies for neovascular age-related macular degeneration show favorable safety, maintained visual acuity, and a reduced treatment burden compared with standard anti-VEGF treatment.
Full story 👉️ buff.ly/dMvwh71
@springermedicine.comFrom #EURETINA2026 - The bioerodible EYP-1901, an intravitreal insert that delivers vorolanib, has failed to show noninferiority to aflibercept 2 mg in patients with wet AMD despite providing strong anatomic control.
👉️ buff.ly/FiihEys
@springermedicine.comFrom #EURETINA2026 - Vision restoration with the PRIMA subretinal neurostimulation system persists in people with geographic atrophy due to age-related macular degeneration for at least 36 months.
Full story 👉️ buff.ly/dqq8nyF
@springermedicine.comStay up to date with the latest news from #EURETINA2026 with our congress hub.
We'll be bringing you the top stories, key highlights, and expert opinions from this year's meeting.
👉️ buff.ly/MbuFgAi
@wisepress.bsky.socialWe’re delighted to be exhibiting at the 26th EURETINA Congress, taking place from 1–4 October 2026 in Vienna, Austria 🇦🇹
Whether you’re looking for the latest clinical resources, specialist textbooks or essential references, come and browse our selection at the Wisepress Bookshop.
@wisepress.bsky.socialWe’re delighted to be exhibiting at the 26th EURETINA Congress, taking place from 1–4 October 2026 in Vienna, Austria 🇦🇹
Whether you’re looking for the latest clinical resources, specialist textbooks or essential references, come and browse our selection at the Wisepress Bookshop.